Cargando…
A Description of the Statistical Methods for the Vaccine Impact on Diarrhea in Africa (VIDA) Study
BACKGROUND: Diarrheal diseases remain a health threat to children in low- and middle-income countries. The Vaccine Impact on Diarrhea in Africa (VIDA) study was a 36-month, prospective, matched case-control study designed to estimate the etiology, incidence, and adverse clinical consequences of mode...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10116558/ https://www.ncbi.nlm.nih.gov/pubmed/37074428 http://dx.doi.org/10.1093/cid/ciac968 |
_version_ | 1785028450176729088 |
---|---|
author | Powell, Helen Liang, Yuanyuan Neuzil, Kathleen M Jamka, Leslie P Nasrin, Dilruba Sow, Samba O Hossain, M Jahangir Omore, Richard Kotloff, Karen L |
author_facet | Powell, Helen Liang, Yuanyuan Neuzil, Kathleen M Jamka, Leslie P Nasrin, Dilruba Sow, Samba O Hossain, M Jahangir Omore, Richard Kotloff, Karen L |
author_sort | Powell, Helen |
collection | PubMed |
description | BACKGROUND: Diarrheal diseases remain a health threat to children in low- and middle-income countries. The Vaccine Impact on Diarrhea in Africa (VIDA) study was a 36-month, prospective, matched case-control study designed to estimate the etiology, incidence, and adverse clinical consequences of moderate-to-severe diarrhea (MSD) in children aged 0–59 months. VIDA was conducted following rotavirus vaccine introduction at 3 censused sites in sub-Saharan Africa that participated in the Global Enteric Multicenter Study (GEMS) ∼10 years earlier. We describe the study design and statistical methods of VIDA and where they differ from GEMS. METHODS: We aimed to enroll 8–9 MSD cases every 2 weeks from sentinel health centers in 3 age strata (0–11, 12–23, 24–59 months) and 1 to 3 controls matched by age, sex, date of case enrollment, and village. Clinical, epidemiological, and anthropometric data were collected at enrollment and ∼60 days later. A stool specimen collected at enrollment was analyzed by both conventional methods and quantitative PCR for enteric pathogens. For the matched case-control study, we estimated the population-based, pathogen-specific attributable fraction (AF) and attributable incidence adjusted for age, site, and other pathogens, and identified episodes attributable to a specific pathogen for additional analyses. A prospective cohort study nested within the original matched case-control study allowed assessment of (1) the association between potential risk factors and outcomes other than MSD status and (2) the impact of MSD on linear growth. CONCLUSIONS: GEMS and VIDA together comprise the largest and most comprehensive assessment of MSD conducted to date in sub-Saharan Africa populations at highest risk for morbidity and mortality from diarrhea. The statistical methods used in VIDA have endeavored to maximize the use of available data to produce more robust estimates of the pathogen-specific disease burden that might be prevented by effective interventions. |
format | Online Article Text |
id | pubmed-10116558 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-101165582023-04-21 A Description of the Statistical Methods for the Vaccine Impact on Diarrhea in Africa (VIDA) Study Powell, Helen Liang, Yuanyuan Neuzil, Kathleen M Jamka, Leslie P Nasrin, Dilruba Sow, Samba O Hossain, M Jahangir Omore, Richard Kotloff, Karen L Clin Infect Dis VIDA Supplement BACKGROUND: Diarrheal diseases remain a health threat to children in low- and middle-income countries. The Vaccine Impact on Diarrhea in Africa (VIDA) study was a 36-month, prospective, matched case-control study designed to estimate the etiology, incidence, and adverse clinical consequences of moderate-to-severe diarrhea (MSD) in children aged 0–59 months. VIDA was conducted following rotavirus vaccine introduction at 3 censused sites in sub-Saharan Africa that participated in the Global Enteric Multicenter Study (GEMS) ∼10 years earlier. We describe the study design and statistical methods of VIDA and where they differ from GEMS. METHODS: We aimed to enroll 8–9 MSD cases every 2 weeks from sentinel health centers in 3 age strata (0–11, 12–23, 24–59 months) and 1 to 3 controls matched by age, sex, date of case enrollment, and village. Clinical, epidemiological, and anthropometric data were collected at enrollment and ∼60 days later. A stool specimen collected at enrollment was analyzed by both conventional methods and quantitative PCR for enteric pathogens. For the matched case-control study, we estimated the population-based, pathogen-specific attributable fraction (AF) and attributable incidence adjusted for age, site, and other pathogens, and identified episodes attributable to a specific pathogen for additional analyses. A prospective cohort study nested within the original matched case-control study allowed assessment of (1) the association between potential risk factors and outcomes other than MSD status and (2) the impact of MSD on linear growth. CONCLUSIONS: GEMS and VIDA together comprise the largest and most comprehensive assessment of MSD conducted to date in sub-Saharan Africa populations at highest risk for morbidity and mortality from diarrhea. The statistical methods used in VIDA have endeavored to maximize the use of available data to produce more robust estimates of the pathogen-specific disease burden that might be prevented by effective interventions. Oxford University Press 2023-04-19 /pmc/articles/PMC10116558/ /pubmed/37074428 http://dx.doi.org/10.1093/cid/ciac968 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | VIDA Supplement Powell, Helen Liang, Yuanyuan Neuzil, Kathleen M Jamka, Leslie P Nasrin, Dilruba Sow, Samba O Hossain, M Jahangir Omore, Richard Kotloff, Karen L A Description of the Statistical Methods for the Vaccine Impact on Diarrhea in Africa (VIDA) Study |
title | A Description of the Statistical Methods for the Vaccine Impact on Diarrhea in Africa (VIDA) Study |
title_full | A Description of the Statistical Methods for the Vaccine Impact on Diarrhea in Africa (VIDA) Study |
title_fullStr | A Description of the Statistical Methods for the Vaccine Impact on Diarrhea in Africa (VIDA) Study |
title_full_unstemmed | A Description of the Statistical Methods for the Vaccine Impact on Diarrhea in Africa (VIDA) Study |
title_short | A Description of the Statistical Methods for the Vaccine Impact on Diarrhea in Africa (VIDA) Study |
title_sort | description of the statistical methods for the vaccine impact on diarrhea in africa (vida) study |
topic | VIDA Supplement |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10116558/ https://www.ncbi.nlm.nih.gov/pubmed/37074428 http://dx.doi.org/10.1093/cid/ciac968 |
work_keys_str_mv | AT powellhelen adescriptionofthestatisticalmethodsforthevaccineimpactondiarrheainafricavidastudy AT liangyuanyuan adescriptionofthestatisticalmethodsforthevaccineimpactondiarrheainafricavidastudy AT neuzilkathleenm adescriptionofthestatisticalmethodsforthevaccineimpactondiarrheainafricavidastudy AT jamkalesliep adescriptionofthestatisticalmethodsforthevaccineimpactondiarrheainafricavidastudy AT nasrindilruba adescriptionofthestatisticalmethodsforthevaccineimpactondiarrheainafricavidastudy AT sowsambao adescriptionofthestatisticalmethodsforthevaccineimpactondiarrheainafricavidastudy AT hossainmjahangir adescriptionofthestatisticalmethodsforthevaccineimpactondiarrheainafricavidastudy AT omorerichard adescriptionofthestatisticalmethodsforthevaccineimpactondiarrheainafricavidastudy AT kotloffkarenl adescriptionofthestatisticalmethodsforthevaccineimpactondiarrheainafricavidastudy AT powellhelen descriptionofthestatisticalmethodsforthevaccineimpactondiarrheainafricavidastudy AT liangyuanyuan descriptionofthestatisticalmethodsforthevaccineimpactondiarrheainafricavidastudy AT neuzilkathleenm descriptionofthestatisticalmethodsforthevaccineimpactondiarrheainafricavidastudy AT jamkalesliep descriptionofthestatisticalmethodsforthevaccineimpactondiarrheainafricavidastudy AT nasrindilruba descriptionofthestatisticalmethodsforthevaccineimpactondiarrheainafricavidastudy AT sowsambao descriptionofthestatisticalmethodsforthevaccineimpactondiarrheainafricavidastudy AT hossainmjahangir descriptionofthestatisticalmethodsforthevaccineimpactondiarrheainafricavidastudy AT omorerichard descriptionofthestatisticalmethodsforthevaccineimpactondiarrheainafricavidastudy AT kotloffkarenl descriptionofthestatisticalmethodsforthevaccineimpactondiarrheainafricavidastudy |